score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625C	0.5536	56.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625C (Missense)		UVM_MUTECT2	TCGA-VD-A8KA-01B-11D-A39W-08	TCGA-VD-A8KA-10A-01D-A39Z-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.K666T	0.4688	64.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.K666T (Missense)		UVM_MUTECT2	TCGA-V4-A9E5-01A-11D-A39W-08	TCGA-V4-A9E5-10A-01D-A39Z-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625C	0.5278	36.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625C (Missense)		UVM_MUTECT2	TCGA-VD-A8K9-01A-11D-A39W-08	TCGA-VD-A8K9-10A-01D-A39Z-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625H	0.4167	60.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625H (Missense)		UVM_MUTECT2	TCGA-VD-A8KH-01A-11D-A39W-08	TCGA-VD-A8KH-10A-01D-A39Z-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625H	0.42	50.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625H (Missense)		UVM_MUTECT2	TCGA-V4-A9F4-01A-11D-A39W-08	TCGA-V4-A9F4-10A-01D-A39Z-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625C	0.431	58.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625C (Missense)		UVM_MUTECT2	TCGA-V4-A9EW-01A-11D-A39W-08	TCGA-V4-A9EW-10A-01D-A39Z-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625H	0.4615	52.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625H (Missense)		UVM_MUTECT2	TCGA-WC-AA9E-01A-11D-A39W-08	TCGA-WC-AA9E-10A-01D-A39Z-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625H	0.4133	75.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625H (Missense)		UVM_MUTECT2	TCGA-V4-A9EZ-01A-11D-A39W-08	TCGA-V4-A9EZ-10A-01D-A39Z-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625H	0.3793	58.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625H (Missense)		UVM_MUTECT2	TCGA-V4-A9E9-01A-11D-A39W-08	TCGA-V4-A9E9-10A-01D-A39Z-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.T663P	0.4255	47.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.T663P (Missense)		UVM_MUTECT2	TCGA-V4-A9EC-01A-11D-A39W-08	TCGA-V4-A9EC-10A-01D-A39Z-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.K666T	0.4308	65.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.K666T (Missense)		UVM_MUTECT2	TCGA-WC-AA9A-01A-11D-A39W-08	TCGA-WC-AA9A-10A-01D-A39Z-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625C	0.4035	57.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625C (Missense)		UVM_MUTECT2	TCGA-VD-A8KB-01A-11D-A39W-08	TCGA-VD-A8KB-10C-01D-A39Z-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625C	0.4058	69.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625C (Missense)		UVM_MUTECT2	TCGA-V4-A9EA-01A-11D-A39W-08	TCGA-V4-A9EA-10A-01D-A39Z-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.H662R	0.5075	67.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.H662R (Missense)		UVM_MUTECT2	TCGA-WC-A881-01A-12D-A39W-08	TCGA-WC-A881-10A-01D-A39Z-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625H	0.4167	48.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625H (Missense)		UVM_MUTECT2	TCGA-WC-A885-01A-11D-A39W-08	TCGA-WC-A885-10A-01D-A39Z-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625H	0.4091	44.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625H (Missense)		UVM_MUTECT2	TCGA-V4-A9EJ-01A-11D-A39W-08	TCGA-V4-A9EJ-10A-01D-A39Z-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625H	0.3478	46.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625H (Missense)		UVM_MUTECT2	TCGA-V4-A9ES-01A-11D-A39W-08	TCGA-V4-A9ES-10A-01D-A39Z-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625C	0.4865	37.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625C (Missense)		UVM_MUTECT2	TCGA-YZ-A985-01A-11D-A39W-08	TCGA-YZ-A985-10A-01D-A39Z-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.V859M	0.2411	112.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.V859M (Missense)	0	UVM_MUTECT2	TCGA-V4-A9F3-01A-11D-A39W-08	TCGA-V4-A9F3-10A-01D-A39Z-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.R177Q	0.1176	34.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.R177Q (Missense)		UVM_MUTECT2	TCGA-YZ-A985-01A-11D-A39W-08	TCGA-YZ-A985-10A-01D-A39Z-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R479Q	0.1667	42.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R479Q (Missense)		UVM_MUTECT2	TCGA-YZ-A985-01A-11D-A39W-08	TCGA-YZ-A985-10A-01D-A39Z-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.E261V	0.0968	31.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.E261V (Missense)		UVM_MUTECT2	TCGA-WC-A88A-01A-11D-A39W-08	TCGA-WC-A88A-10A-01D-A39Z-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.D718H	0.5283	53.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.D718H (Missense)		UVM_MUTECT2	TCGA-V4-A9ES-01A-11D-A39W-08	TCGA-V4-A9ES-10A-01D-A39Z-08
Investigate Actionability	FDA-Approved			Somatic Variant	FANCL	Missense	p.Y339H	0.2326	43.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	FANCL p.Y339H (Missense)	0	UVM_MUTECT2	TCGA-V4-A9EC-01A-11D-A39W-08	TCGA-V4-A9EC-10A-01D-A39Z-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Splice Site	p.X161_splice	0.7273	11.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.X161_splice (Splice Site)		UVM_MUTECT2	TCGA-WC-A883-01A-12D-A39W-08	TCGA-WC-A883-10A-01D-A39Z-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.Q581L	0.0571	105.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q581L (Missense)		UVM_MUTECT2	TCGA-V4-A9EZ-01A-11D-A39W-08	TCGA-V4-A9EZ-10A-01D-A39Z-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.T910M	0.7222	18.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.T910M (Missense)		UVM_MUTECT2	TCGA-YZ-A985-01A-11D-A39W-08	TCGA-YZ-A985-10A-01D-A39Z-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.S395F	0.4737	114.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.S395F (Missense)		UVM_MUTECT2	TCGA-YZ-A985-01A-11D-A39W-08	TCGA-YZ-A985-10A-01D-A39Z-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Nonsense	p.S360*	0.1167	180.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.S360* (Nonsense)		UVM_MUTECT2	TCGA-VD-A8KJ-01A-11D-A39W-08	TCGA-VD-A8KJ-10A-01D-A39Z-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.G1903R	0.1944	72.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.G1903R (Missense)		UVM_MUTECT2	TCGA-YZ-A985-01A-11D-A39W-08	TCGA-YZ-A985-10A-01D-A39Z-08
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Missense	p.T273M	0.1978	91.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.T273M (Missense)		UVM_MUTECT2	TCGA-YZ-A985-01A-11D-A39W-08	TCGA-YZ-A985-10A-01D-A39Z-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Frameshift	p.V331*	0.25	24.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.V331* (Frameshift)		UVM_MUTECT2	TCGA-WC-A87W-01A-11D-A39W-08	TCGA-WC-A87W-10A-01D-A39Z-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Deletion	p.S311_T312del	0.3333	9.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.S311_T312del (Deletion)		UVM_MUTECT2	TCGA-V4-A9EC-01A-11D-A39W-08	TCGA-V4-A9EC-10A-01D-A39Z-08
Biologically Relevant				Somatic Variant	EWSR1	Nonsense	p.Y86*	0.5417	24.0	0.0	0.0																									EWSR1 p.Y86* (Nonsense)		UVM_MUTECT2	TCGA-V4-A9EL-01A-11D-A39W-08	TCGA-V4-A9EL-10A-01D-A39Z-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P495L	0.95	20.0	0.0	0.0																									ROS1 p.P495L (Missense)		UVM_MUTECT2	TCGA-VD-A8KB-01A-11D-A39W-08	TCGA-VD-A8KB-10C-01D-A39Z-08
Biologically Relevant				Somatic Variant	FGFR2	Nonsense	p.R210*	0.4865	74.0	0.0	0.0																									FGFR2 p.R210* (Nonsense)		UVM_MUTECT2	TCGA-WC-A885-01A-11D-A39W-08	TCGA-WC-A885-10A-01D-A39Z-08
Biologically Relevant				Microsatellite Stability	Supporting variants		JAK1 p.X161_splice (Splice Site)																													Supporting variants: JAK1 p.X161_splice (Splice Site)		UVM_MUTECT2		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	1.0																													COSMIC Signature (version 2) 1 (100%)		UVM_MUTECT2		
